Tetragon Partners GP Ltd 13F holdings, Q4 2025
Holdings as of December 31, 2025 · filings on SEC EDGAR · latest filing →
Tetragon Partners GP Ltd disclosed 28 US equity positions worth $474.3m in its Q4 2025 13F filing. The largest position was PATH at 60.3% of the reported book, followed by KGEI and LYFT. Against the Q3 2025 filing, it opened 9 new positions, added to 7 and reduced 6 among the top 28 holdings.
What did Tetragon Partners GP Ltd own in Q4 2025? Top 28 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2025 |
|---|---|---|---|---|---|---|---|
| 1 | PATH UIPATH INC | Technology | 60.3% | $286.0m | 17,450,000 | 3% | added |
| 2 | KGEI KOLIBRI GLOBAL ENERGY INC | 5.7% | $27.3m | 6,934,504 | -2% | reduced | |
| 3 | LYFT LYFT INC | Technology | 4.1% | $19.4m | 1,000,000 | 0% | held |
| 4 | AUTL AUTOLUS THERAPEUTICS PLC | Healthcare | 4.0% | $18.9m | 9,500,000 | 0% | held |
| 5 | CXM SPRINKLR INC | Technology | 3.6% | $17.1m | 2,200,000 | 0% | held |
| 6 | WK WORKIVA INC | Technology | 2.7% | $12.9m | 150,000 | 0% | held |
| 7 | ANNX ANNEXON INC | Healthcare | 2.2% | $10.2m | 2,032,455 | -4% | reduced |
| 8 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 1.4% | $6.8m | 22,952 | – | new |
| 9 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 1.4% | $6.6m | 243,800 | -20% | reduced |
| 10 | ARWR ARROWHEAD PHARMACEUTICALS IN | Healthcare | 1.4% | $6.4m | 96,935 | 18% | added |
| 11 | PHVS PHARVARIS N V | 1.1% | $5.4m | 194,612 | 0% | held | |
| 12 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.0% | $4.9m | 26,934 | -42% | reduced |
| 13 | DYN DYNE THERAPEUTICS INC | Healthcare | 1.0% | $4.9m | 247,997 | 11% | added |
| 14 | MBX MBX BIOSCIENCES INC | Healthcare | 1.0% | $4.5m | 143,327 | -19% | reduced |
| 15 | RAPT RAPT THERAPEUTICS INC | 0.9% | $4.5m | 131,770 | – | new | |
| 16 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 0.9% | $4.4m | 162,018 | – | new |
| 17 | IMVT IMMUNOVANT INC | Healthcare | 0.9% | $4.2m | 166,187 | -12% | reduced |
| 18 | ALKS ALKERMES PLC | Healthcare | 0.8% | $3.9m | 141,172 | 58% | added |
| 19 | AM6 AMICUS THERAPEUTICS INC | 0.8% | $3.7m | 260,771 | 115% | added | |
| 20 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 0.7% | $3.3m | 272,828 | 6% | added |
| 21 | HRMY HARMONY BIOSCIENCES HLDGS IN | Healthcare | 0.7% | $3.1m | 82,824 | – | new |
| 22 | NKTR NEKTAR THERAPEUTICS | Healthcare | 0.6% | $2.9m | 69,287 | – | new |
| 23 | KRYS KRYSTAL BIOTECH INC | Healthcare | 0.6% | $2.9m | 11,814 | 143% | added |
| 24 | MPLT MAPLIGHT THERAPEUTICS INC | 0.6% | $2.9m | 164,525 | – | new | |
| 25 | SLN SILENCE THERAPEUTICS PLC | 0.5% | $2.2m | 365,369 | – | new | |
| 26 | SNOW SNOWFLAKE INC | Technology | 0.5% | $2.2m | 10,000 | 0% | held |
| 27 | ZVRA ZEVRA THERAPEUTICS INC | 0.4% | $1.7m | 192,518 | – | new | |
| 28 | AVADEL PHARMACEUTICALS PLC | 0.2% | $943.1k | 43,763 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.